Arrowhead Pharmaceuticals (ARWR) Given Buy Rating at Chardan Capital

Arrowhead Pharmaceuticals (NASDAQ:ARWR)‘s stock had its “buy” rating restated by stock analysts at Chardan Capital in a research report issued on Monday. They currently have a $17.50 price objective on the biotechnology company’s stock. Chardan Capital’s price target indicates a potential upside of 7.03% from the stock’s previous close.

Several other research firms also recently issued reports on ARWR. Cantor Fitzgerald reissued an “overweight” rating and issued a $13.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, August 8th. Jefferies Financial Group reissued a “buy” rating and issued a $20.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, August 8th. B. Riley upped their target price on Arrowhead Pharmaceuticals from $12.00 to $18.00 and gave the company a “neutral” rating in a research report on Wednesday, August 8th. Piper Jaffray Companies reissued an “overweight” rating and issued a $17.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Friday, June 29th. Finally, S&P Equity Research cut their target price on Arrowhead Pharmaceuticals from $13.76 to $11.68 in a research report on Monday, June 18th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $16.20.

Shares of ARWR opened at $16.35 on Monday. Arrowhead Pharmaceuticals has a 12 month low of $1.90 and a 12 month high of $17.50. The company has a quick ratio of 8.69, a current ratio of 8.69 and a debt-to-equity ratio of 0.02. The firm has a market cap of $1.49 billion, a PE ratio of -35.62 and a beta of 1.85.



Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings data on Tuesday, August 7th. The biotechnology company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.01. Arrowhead Pharmaceuticals had a negative return on equity of 59.39% and a negative net margin of 400.13%. The firm had revenue of $0.73 million during the quarter, compared to analyst estimates of $0.62 million. analysts forecast that Arrowhead Pharmaceuticals will post -0.69 earnings per share for the current year.

In related news, CFO Kenneth Allen Myszkowski sold 20,000 shares of the company’s stock in a transaction on Tuesday, June 19th. The stock was sold at an average price of $14.01, for a total value of $280,200.00. Following the transaction, the chief financial officer now directly owns 330,815 shares of the company’s stock, valued at approximately $4,634,718.15. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 4.60% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently made changes to their positions in the business. UBS Group AG grew its position in Arrowhead Pharmaceuticals by 798.0% during the 1st quarter. UBS Group AG now owns 202,765 shares of the biotechnology company’s stock worth $1,462,000 after purchasing an additional 180,186 shares during the period. Macquarie Group Ltd. acquired a new stake in Arrowhead Pharmaceuticals during the 4th quarter worth about $123,000. Jane Street Group LLC acquired a new stake in Arrowhead Pharmaceuticals during the 4th quarter worth about $130,000. Element Capital Management LLC acquired a new stake in Arrowhead Pharmaceuticals during the 1st quarter worth about $851,000. Finally, BlackRock Inc. grew its position in Arrowhead Pharmaceuticals by 23.8% during the 1st quarter. BlackRock Inc. now owns 3,403,940 shares of the biotechnology company’s stock worth $24,543,000 after purchasing an additional 655,112 shares during the period. 47.20% of the stock is currently owned by institutional investors.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target.

Recommended Story: Outstanding Shares, Buying and Selling Stocks

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply